Theriva Biologics, Inc.TOVXNYSE
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+336.5%
5Y CAGR+19.7%
Year-over-Year Change
Year-over-year operating income growth rate
3Y CAGR
+336.5%/yr
Quarterly compound
5Y CAGR
+19.7%/yr
Recent acceleration
Percentile
P100
Near historical high
vs 5Y Ago
2.5x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 66.19% |
| Q2 2025 | -197.31% |
| Q1 2025 | -0.50% |
| Q4 2024 | 44.28% |
| Q3 2024 | 7.08% |
| Q2 2024 | -57.42% |
| Q1 2024 | 8.27% |
| Q4 2023 | -39.36% |
| Q3 2023 | 27.53% |
| Q2 2023 | -12.40% |
| Q1 2023 | 29.23% |
| Q4 2022 | -46.75% |
| Q3 2022 | 0.80% |
| Q2 2022 | -18.20% |
| Q1 2022 | 19.24% |
| Q4 2021 | -60.76% |
| Q3 2021 | -2.44% |
| Q2 2021 | -26.01% |
| Q1 2021 | -19.00% |
| Q4 2020 | -0.99% |
| Q3 2020 | 26.93% |
| Q2 2020 | 4.59% |
| Q1 2020 | 5.67% |
| Q4 2019 | 38.76% |
| Q3 2019 | -44.09% |
| Q2 2019 | -1.85% |
| Q1 2019 | -9.64% |
| Q4 2018 | 24.58% |
| Q3 2018 | 13.65% |
| Q2 2018 | -0.26% |
| Q1 2018 | 13.71% |
| Q4 2017 | 1.01% |
| Q3 2017 | 9.78% |
| Q2 2017 | 20.54% |
| Q1 2017 | 20.14% |
| Q4 2016 | -11.45% |
| Q3 2016 | 1.66% |
| Q2 2016 | 12.00% |
| Q1 2016 | 7.13% |
| Q4 2015 | 2.21% |